Tseng Alice, Seet Jason, Phillips Elizabeth J
University Health Network, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Br J Clin Pharmacol. 2015 Feb;79(2):182-94. doi: 10.1111/bcp.12403.
The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
人类免疫缺陷病毒(HIV)治疗的发展增进了我们对复杂药理学问题的理解与管理,这些问题推动了HIV感染患者治疗效果的改善和生活质量的提高。这些问题包括依从性、长期和短期毒性、药物增强、药物基因组学、治疗药物监测、药物向中枢神经系统、生殖道和小肠等免疫赦免部位的差异渗透,以及与细胞色素P450药物代谢酶、尿苷二磷酸葡萄糖醛酸转移酶和药物转运体相关的药物相互作用和药物-食物相互作用等等。随着对HIV免疫发病机制的深入了解以及全球公共卫生倡议推动新的治疗方法,目标是预防、控制并最终根除HIV,未来充满希望。